The Antibiotic Resistance Crisis Has a Troubling Twist
WiredAPR 2023
Market forces alone are not enough to ensure that essential drugs needed to protect public health will be produced. This legislation would guarantee that funds are made available to continue to develop and produce treatments for drug-resistant bacteria and fungi.
While it is important to encourage pharmaceutical companies to produce antibiotics, this type of legislation is not the answer. It fails to set the minimum requirements of acceptable clinical trial standards and is essentially just a giveaway to the pharmaceutical industry.